跳至主要内容
临床试验/RPCEC00000319
RPCEC00000319已完成未知

Evaluation of the efficacy and safety of a new BIOMODULINA T® dosage scheme for the prevention of infections, including COVID-19, in older adults in Cuba. Confirmatory study (COVID-19)

Centro Nacional de Biopreparados (BIOCEN)0 个研究点目标入组 160 人开始时间: 2020年5月29日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
60 years 至 one(—)
性别
All

入选标准

  • 1. Patients who meet the diagnostic criteria
  • 2. Any sex and skin color aged 60 years and over.
  • 3. Patients who express their consent in writing, to participate in the study and in case major cognitive impairment is present, be signed by a family member, tutor or caregiver.

排除标准

  • 1. Patients who have received treatment with BIOMODULINA T® in the previous two months.
  • 2. Patients with known hypersensitivity to any component of the formulation.
  • 3. Patients with acute allergic states or history of severe allergic reactions.
  • 4. Patients with uncontrolled breakthrough diseases including, but not limited to: acute infections with concomitant febrile illness, symptomatic congestive heart failure, unstable angina pectoris.

研究者

发起方
Centro Nacional de Biopreparados (BIOCEN)

相似试验